Lofexidine Tablet, Coated
Product Images NDC 71921-250

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Lofexidine (NDC 71921-250). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Florida Pharmaceutical Products, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Lofexidine-structure (Lofexidien Structure)

Chemical structure diagram of Lofexidine hydrochloride showing its molecular composition including a dichlorophenyl group and a piperidine ring with an imidazoline moiety.*

FDA Label Image

Lofexidine-carton-96-tablets (Lofexidine Carton 96 Tablets)

Packaging label for Lofexidine Tablets 0.18 mg, a coated oral tablet. The label shows the product name, strength, NDC 71921-250-96, and quantity of 96 tablets. It is labeled Rx Only and includes storage instructions and manufacturer information for Florida Pharmaceutical Products, LLC. The label also displays barcodes and warnings to keep out of reach of children.*

FDA Label Image

Lofexidine-container-96-tablets (Lofexidine Container 96 Tablets)

Label for Lofexidine Tablets 0.18 mg, coated oral tablets, with a package count of 96 tablets. The label includes storage instructions, manufacturer Indoco Remedies Limited (India), and labeler Florida Pharmaceutical Products, LLC. It features barcodes, NDC 71921-250, and safety warnings such as keeping out of reach of children and protecting from heat and moisture.*

FDA Label Image

Fig-1 (Lofexidine Fig 1)

A Kaplan-Meier survival curve chart showing the proportion of subjects completing a treatment period over study days 1 to 7. The chart compares three groups: Lofexidine 2.16 mg, Lofexidine 2.88 mg, and placebo. The vertical axis represents the proportion of subjects completing treatment, while the horizontal axis shows study days.*

FDA Label Image

Fig-2 (Lofexidine Fig 2)

A line graph showing mean SOWS-Gossop scores over seven study days comparing Lofexidine at 2.16 mg, 2.88 mg, and placebo groups. The y-axis presents score values; the x-axis represents study days from 1 to 7. Confidence intervals (95% CI) are indicated for each group with different line styles and error bars.*

FDA Label Image

Fig-3 (Lofexidine Fig 3)

A line graph showing the proportion of subjects completing the treatment period over an 8-day study. The graph compares two groups: one receiving Lofexidine 2.88 mg and the other a placebo. The y-axis represents the proportion of subjects completing treatment, ranging from 0 to 1, and the x-axis represents study days from 1 to 8.*

FDA Label Image

Fig-4 (Lofexidine Fig 4)

A line graph comparing mean Subjective Opiate Withdrawal Scale (SOWS) Gossoop scores over five study days between Lofexidine 2.88 mg and placebo. The vertical axis shows the mean score with 95% confidence intervals, and the horizontal axis indicates study days from 1 to 5. Lofexidine data are shown with solid lines and placebo with dashed lines.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.